HEPA (hepionpharma.com) Bathi resik

Hepion Pharmaceuticals' business profitability correlates with the implementation of AI to optimize liver therapy, while the 0.00 indicator expresses the state of the metric. Capitalization growth relies on the commercialization of Rensifilvim against fibrosis and MASH. Hepion Pharmaceuticals is currently undergoing clinical trials, confirming the efficacy of its innovative developments in combating severe hepatology pathologies.

HEPA (Hepion Pharmaceuticals Inc.) riwayat Bathi resik perusahaan saka 04.07.2022 nganti 14.06.2025

Rincian metrik komprehensif lan analitis hepionpharma.com (HEPA)

- rega lan prakiraan konsensus rega:

Kutipan saham Hepion Pharmaceuticals, Inc.|HEPA - Prakiraan konsensus analis

- indikator valuasi pasar bisnis:

Kapitalisasi pasar Hepion Pharmaceuticals, Inc.|HEPA - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Nilai Akuntansi Saham Hepion Pharmaceuticals|HEPA - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku hepionpharma.com|HEPA - Total Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Koefisien Total Utang marang Modal Hepion Pharmaceuticals|HEPA - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Hepion Pharmaceuticals, Inc.|HEPA - Gunggung utang perusahaan|Utang-utang marang nilai buku Hepion Pharmaceuticals, Inc.|HEPA - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Hepion Pharmaceuticals|Rasio jangkoan perantara hepionpharma.com

- indikator pendapatan resik lan kelipatan nilai:

HEPA - Bathi resik

Pambiji fundamental:HEPA Hepion Pharma

Produk seri Hepion Pharmaceuticals, Inc.

Investors must evaluate long-term business viability through net income, which captures daily operational efficiency and separates market noise from a systemic crisis. An analysis of the company's bottom line reveals Hepion Pharmaceuticals (HEPA) has a critical dependence on external financing, as the absence of commercial products and the suspension of clinical trials make profitability unattainable without a strategic partner.

Pesaing utama